This regimen didn’t prevent infection in all immunized groups after rectal SIVmac251 challenge, but viremia was reduced at 2 and 24 weeks in the best responders, those that received CpG-B DNA and FLT3-L. Although blood DCs can be activated and expanded during cytokine administration, previous studies did not clarify the extent to which mobilization occurred in macaque tissues, especially in BM where DC progenitors develop from CD34+stem cells. 4750Since DCs play important roles in both innate and adaptive immunity, loss and/or impairment of these cells Cinaciguat hydrochloride could exacerbate immune dysfunction observed during lentivirus disease. increased up to 45-fold in blood, lymph nodes, and bone marrow (BM), with DC expansion in the BM preceding mobilization in blood and lymphoid tissues. FLT3-L also increased serum levels of IL-12, at least transiently, and elicited higher surface expression of HLA-DR and the activation markers CD25 and CD69 on NK and T cells. During and after treatment of infected animals, APCs increased in number and were activated; however, CD4+T cell numbers, virion RNA, and anti-SIV/SHIV antibody titers remained relatively stable, suggesting that FLT3-L might be a safe modality to expand DC populations and provide therapeutic benefit during chronic lentivirus infections. == Introduction == Dendritic cells(DCs) are antigen-presenting cells (APCs) that link the innate and adaptive immune systems by recognizing pathogens and initiating humoral and cell-mediated immune responses. Two major types of DCs circulate in human blood: CD11c+myeloid (mDCs) and CD123+plasmacytoid (pDCs). In general, mDCs are more qualified than pDCs at presenting antigen (Ag) to naive T cells1,2; however, Hoeffelet al.3recently showedin vitrothat human pDCs cross-present HIV-1 epitopes, (as lipopeptides), or after uptake of HIV-1 Ags in apoptotic cells, as efficiently as mDCs. Following recognition of pathogen-associated molecular patterns contained in bacteria and viruses by toll-like receptors (TLRs), both DC subsets secrete Cinaciguat hydrochloride cytokines and upregulate the costimulatory molecules CD80 and CD86.4,5On virus activation pDCs secrete more interferon (IFN)- per cell than other cell types and are called IFN-producing cells.6Furthermore, mDCs and pDCs act synergistically to mediate immune responses against HIV-1 and tumor cells and to enhance the development and activation of regulatory T (Treg) and NK cells.711 Studies on mDCs and pDCs typically focus on cells in blood, but both DC subsets in various stages of development are common in murine, macaque (Macaca), and human bone marrow (BM), their site of origin.1215DCs also accumulate in respiratory mucosae following allergic stimuli and in cerebrospinal fluid during bacterial meningitis, induce antiviral responses in the vaginal mucosa, and can be isolated from human tonsils, thymus, lungs, liver, kidney, colon, and peripheral lymph nodes (LNs).1624Reduction in Rabbit polyclonal to PARP14 the numbers and functions of circulating mDCs and pDCs can occur during viral infections, such as with hepatitis B and C viruses, human T cell leukemia virus, SARS coronavirus, and HIV-1.2531We and others showed that DC numbers are reduced in blood and secondary lymphoid organs of rhesus (Macaca mulatta) and pigtailed macaques (M. nemestrina) acutely and chronically infected with SIV.3234Characterization of pDCs in BM of normal pigtailed macaques Cinaciguat hydrochloride also revealed that while these cells are less mature phenotypically than their blood counterparts, they were responsive to microbial stimuli.15,35 Because of their importance in initiating immune responses to pathogens and Ags in vaccine formulations, developing novel strategies to mobilize, by activation and/or maturation, DC populationsin vivois a valid goal. CD34+myeloid and lymphoid progenitor cells have high levels of Fms-like tyrosine kinase 3 (FLT3) receptors on their cell surfaces.36,37The ligand for FLT3 (FLT3-L) is a cytokine expressed in most tissues, but it is at the highest levels on peripheral blood mononuclear cells (PBMCs). A soluble isoform of FLT3-L is also present in human blood at concentrations typically between 50 and 100 pg/ml.38FLT3-L is elevated in serum from patients undergoing chemotherapy, and abnormally high levels are associated with hematologic disorders and autoimmune diseases.3941Initially, murine studies showed that 9 days of subcutaneous inoculation of FLT3-L increased functional splenic DCs up to 17-fold.37,42,43After human stem cell transplantation, administration of FLT3-L to patients elicited increases in DC numbers and enhanced recovery of DC and NK cell subsets.4446FLT3-L-induced DC expansion, with subsequent emigration from BM, was first performed in macaques using a 10-day regimen that efficiently led to activated and increased numbers of DCs in blood,47but Teleshovaet al.48showed that a 7-day regimen was equally effective. Similar experiments using a chimeric FLT3 and granulocyte colony-stimulating factor (G-CSF) receptor agonist, progenipoietin-1 (ProGP), were performed in naive and SIVmac32H-infected macaques.49ProGP induced as much as a 50-fold expansion of blood DCs, but this increase was insufficient to augment responses to HIV Ags elicited Cinaciguat hydrochloride by DNA vaccination and to protect macaques against challenge with SHIV-89.6P.50In contrast, Kwissaet al.51inoculated macaques with FLT3-L for 14 days followed by immunization, either alone or with CpG-B DNA, a TLR9 ligand, with plasmid DNA (recombinant vaccinia virus Ankara, rMVA) expressing both SIV and HIV proteins. Their results exhibited that by day 14 of FLT3-L treatment, activation enhanced expression of CD86 on mDCs and monocytes and, after boosting twice with rMVA, the number of CD8+T cells expressing IFN- increased. This regimen did not prevent infection in all immunized groups after rectal SIVmac251 challenge, but viremia was reduced at 2 and 24 weeks in the best responders, those that received CpG-B DNA and FLT3-L. Although blood DCs can be.